• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue

tetano

Editor, Senior Moderator
Hum Vaccin Immunother. 2015 May 21:0. [Epub ahead of print]
[h=1]Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue.[/h] Prinsen H[SUP]1[/SUP], van Laarhoven HW, Pots JM, Duiveman-de Boer T, Mulder SF, van Herpen CM, Jacobs JF, Leer JW, Bleijenberg G, Stelma FF, Torensma R, de Vries IJ.
[h=3]Author information[/h]

[h=3]Abstract[/h] The aim of this study was to compare humoral and cellular immune responses to influenza vaccination in cancer survivors with and without severe symptoms of fatigue. Severely fatigued (n=15) and non-fatigued (n=12) disease-free cancer survivors were vaccinated against seasonal influenza. Humoral immunity was evaluated at baseline and post-vaccination by a hemagglutination inhibition assay. Cellular immunity was evaluated at baseline and post-vaccination by lymphocyte proliferation and activation assays. Regulatory T cells were measured at baseline by flow cytometry and heat-shock protein 90 levels by ELISA. Comparable humoral immune responses were observed in fatigued and non-fatigued patients, both pre- and post-vaccination. At baseline, fatigued patients showed a significantly diminished cellular proliferation upon virus stimulation with strain H3N2 (1414?1201 counts), and a trend in a similar direction with strain H1N1 (3025?2339 counts), compared to non-fatigued patients (3099?2401 and 5877?4604 counts, respectively). The percentage of regulatory T lymphocytes was significantly increased (4.4?2.1% versus 2.4?0.8%) and significantly lower amounts of interleukin 2 were detected prior to vaccination in fatigued compared to non-fatigued patients (36.3?44.3 pg/ml versus 94.0?45.4 pg/ml with strain H3N2 and 28.4?44.0 pg/ml versus 74.5?56.1 pg/ml with strain H1N1). Pre-vaccination heat-shock protein 90 concentrations, post-vaccination cellular proliferation, and post-vaccination cytokine concentrations did not differ between both groups. In conclusion, influenza vaccination is favorable for severely fatigued cancer survivors and should be recommended when indicated. However, compared to non-fatigued cancer survivors, fatigued cancer survivors showed several significant differences in immunological reactivity at baseline, which warrants further investigation.


[h=4]KEYWORDS:[/h] CBT cognitive behavior therapy; CIS-fatigue Checklist Individual Strength fatigue subscale; Cancer; Fatigue; HI hemagglutination-inhibition; HSP90α human heat shock protein 90 alpha; IFN- γ interferon gamma; IL-10 interleukin 10; IL-2 interleukin 2; IL-4 interleukin 4; IL-5 interleukin 5; Immunity; Influenza; PBMC peripheral blood mononuclear cells; PHA phytohemagglutinin; RUNMC Radboud University Nijmegen Medical Centre; Treg regulatory T lymphocytes; Vaccination

PMID: 25996472 [PubMed - as supplied by publisher]
 
Back
Top Bottom